INMD — InMode Ltd.

Is INMD overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Devices

Oversold As of October 3, 2026

InMode Ltd. (INMD) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Medical Devices) last closed at $14.09. The rating moved from Neutral to Oversold on October 2, 2026.

See all oversold Healthcare stocks →

AI analysis

InMode Ltd. (INMD) is a med‑aesthetics device and consumables company with a sizable installed base that supports recurring revenue and favorable unit economics. Near-term performance hinges on elective-procedure demand, consumables pull‑through and timely execution on product rollouts; market risk-off and investor caution toward device/consumer-health offerings are constraining sentiment. Given limited company-specific filing detail in the provided data and the discretionary nature of the end market, expect range-bound trading with downside sensitivity if consumer spending or procedural volumes weaken.

Key factors

  • InMode Ltd. (INMD) has a meaningful installed base of aesthetic devices which supports recurring consumable sales and procedure-level economics.
  • Revenue sensitivity to discretionary elective-procedure demand; consumer sentiment and macro conditions drive near-term procedure volumes.
  • Historically strong gross margins on devices and consumables provide operating leverage when utilization is stable.
  • Market-wide risk-off and a cooling IPO window for device/consumer-health offerings are weighing on sentiment and access to capital for sector peers.
  • Limited recent company-specific public filing detail in the provided data set increases reliance on observable demand trends and installed-base dynamics.
  • Competition from other medical-aesthetics device vendors and potential product-substitution/innovation risk could pressure share and pricing over time.

Risks

  • Decline in elective aesthetic procedure volumes from macro slowdown, higher rates, or reduced consumer discretionary spending.
  • Intensifying competition and faster innovation cycles from rivals leading to share loss or pricing pressure.
  • Supply-chain disruptions or component shortages that delay product shipments or new-rollout timelines.
  • Regulatory actions, safety recalls, or adverse clinical reports that could restrict device use or increase compliance costs.
  • Weak capital markets / investor sentiment for device names (IPO window cooling) limiting access to financing or pressuring valuation.
  • Limited visibility into near-term quarterly results due to absence of recent detailed filings in the provided dataset; execution risk remains.

See today's live rating, score and targets

Members see the live hourly rating for INMD — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.